Company

Bio-inspired technology
for the next generation
of medicine

Novelgen Co., Ltd. develops functional biomaterials based on recombinant mussel foot proteins.

Philosophy

Vision

Solve regenerative and advanced medicine's unmet needs through bio-inspired technology, improving human health and quality of life.

Mission

1. Deliver safe, sustainable, animal-free biomaterials.
2. Build products that unite regulatory fit and clinical utility.
3. Set technology standards in the global market.

Values

Scientific rigor

Peer-reviewed, evidence-first development.

Regulatory fluency

Early engagement with PMDA / FDA / EMA.

Partnership

Strategic collaboration with pharma / medtech.

Innovation

Continuous R&D investment and IP portfolio.

Company details

Name: Novelgen Co., Ltd. (株式会社ノベルジェン)
Founded: October 2019
CEO: Atsushi OGURA, Ph.D. (小倉淳)
Address: 1281-8-15 Tamura-cho, Nagahama, Shiga 526-0829, Japan
Phone: +81-50-5369-0762
Email: office@novelgen.jp
Capital: JPY 20 million
Employees: 21

Team

Atsushi Ogura, Ph.D. / 小倉淳

Founder, CEO

Concurrent professor at the Nagahama Institute of Bio-Science and Technology. Leads scientific direction and business strategy, bringing marine and microalgae biotech into practical applications.

Expertise

Genomics
Microalgae
Functional proteins
Bioinformatics

Responsibilities

• Overall research roadmap
• Coordination with major research partners
• Regulatory / pharmaceutical strategy

Education

• The University of Tokyo, Faculty of Agriculture (genetic engineering)
• The University of Tokyo Graduate School of Agricultural and Life Sciences (microbiology / algae)
• SOKENDAI (Genomics)

Achievements

• Secured substantial R&D funding including AMED grants
• Active teaching and research at Nagahama Institute of Bio-Science and Technology

Koichi Kudo

CSO (Chief Strategy Officer)

IP practice at food, pharma and chemical companies combined with strategy consulting experience. Drives Novelgen's IP, licensing and international expansion.